FR08C0041I2 - - Google Patents
Info
- Publication number
- FR08C0041I2 FR08C0041I2 FR08C0041C FR08C0041C FR08C0041I2 FR 08C0041 I2 FR08C0041 I2 FR 08C0041I2 FR 08C0041 C FR08C0041 C FR 08C0041C FR 08C0041 C FR08C0041 C FR 08C0041C FR 08C0041 I2 FR08C0041 I2 FR 08C0041I2
- Authority
- FR
- France
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/20—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with no nitrogen atoms directly attached to a ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/30—Only oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/48—Two nitrogen atoms
- C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4436851 | 1994-10-14 | ||
DE19533023A DE19533023B4 (de) | 1994-10-14 | 1995-09-07 | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
PCT/EP1995/003963 WO1996011914A1 (fr) | 1994-10-14 | 1995-10-07 | Nouveaux derives d'acide carboxylique, leur preparation et leur utilisation |
Publications (2)
Publication Number | Publication Date |
---|---|
FR08C0041I1 FR08C0041I1 (fr) | 2008-11-28 |
FR08C0041I2 true FR08C0041I2 (fr) | 2009-12-18 |
Family
ID=6530833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR08C0041C Active FR08C0041I2 (fr) | 1994-10-14 | 2008-10-21 |
Country Status (32)
Country | Link |
---|---|
US (15) | USRE42462E1 (fr) |
EP (2) | EP0785926B1 (fr) |
JP (6) | JP3957748B2 (fr) |
KR (1) | KR100438339B1 (fr) |
CN (3) | CN1923820B (fr) |
AT (2) | ATE204568T1 (fr) |
BR (1) | BR9509338A (fr) |
CA (1) | CA2201785C (fr) |
CZ (1) | CZ294603B6 (fr) |
DE (4) | DE19533023B4 (fr) |
DK (1) | DK0785926T3 (fr) |
ES (2) | ES2226996T3 (fr) |
FI (1) | FI120492B (fr) |
FR (1) | FR08C0041I2 (fr) |
GR (1) | GR3036931T3 (fr) |
HK (2) | HK1066541A1 (fr) |
HR (2) | HRP950517B1 (fr) |
HU (1) | HU220621B1 (fr) |
IL (1) | IL115560A (fr) |
LU (1) | LU91487I2 (fr) |
MX (1) | MX9702658A (fr) |
NL (1) | NL300361I2 (fr) |
NO (2) | NO308846B1 (fr) |
NZ (1) | NZ294849A (fr) |
PL (1) | PL186850B1 (fr) |
PT (1) | PT785926E (fr) |
RU (1) | RU2180335C2 (fr) |
SI (1) | SI9520110A (fr) |
TW (1) | TW577880B (fr) |
UA (1) | UA45985C2 (fr) |
WO (1) | WO1996011914A1 (fr) |
ZA (1) | ZA958642B (fr) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19533023B4 (de) * | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
DE19536891A1 (de) * | 1995-10-04 | 1997-04-10 | Basf Ag | Neue Aminosäurederivate, ihre Herstellung und Verwendung |
DE19614533A1 (de) * | 1996-04-12 | 1997-10-16 | Basf Ag | Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung |
DE19614534A1 (de) * | 1996-04-12 | 1997-10-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
DE19636046A1 (de) * | 1996-09-05 | 1998-03-12 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten |
JP2001506243A (ja) * | 1996-12-18 | 2001-05-15 | ビーエーエスエフ アクチェンゲゼルシャフト | 複素環式カルボン酸誘導体、その製造およびエンドセリン受容体拮抗物質としての使用 |
US6030975A (en) * | 1997-03-14 | 2000-02-29 | Basf Aktiengesellschaft | Carboxylic acid derivatives, their preparation and use in treating cancer |
NZ502660A (en) * | 1997-09-04 | 2002-02-01 | Basf Ag | Pyrimidyl- or (oxazolyl- or thiazolyl-)oxy substituted carboxylic acid derivatives useful as mixed ETA/ETB endothelin-receptor antagonists |
AU750755B2 (en) * | 1997-09-26 | 2002-07-25 | Abbvie Deutschland Gmbh & Co Kg | Endothelin antagonist and a renin-angiotensin system inhibitor as a combined preparation |
DE19743142A1 (de) * | 1997-09-30 | 1999-04-01 | Knoll Ag | Pharmazeutische Kombinationspräparate |
DE19743143A1 (de) * | 1997-09-30 | 1999-04-01 | Knoll Ag | Pharmazeutische Kombinationspräparate |
DE19743681A1 (de) * | 1997-10-02 | 1999-04-08 | Knoll Ag | Methode zur Verhinderung der Transplantatabstoßung |
WO1999023078A2 (fr) * | 1997-10-31 | 1999-05-14 | Basf Aktiengesellschaft | Nouveaux derives d'acide carboxylique, portant des chaines laterales amidees; leur mode de production et leur utilisation en tant qu'antagonistes recepteurs d'endotheline |
DE19750529A1 (de) | 1997-11-14 | 1999-05-20 | Basf Ag | Neue heterocyclisch substituierte alpha-Hydroxycarbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten |
DE19806438A1 (de) * | 1998-02-17 | 1999-08-19 | Basf Ag | Neue Carbonsäurederivate mit 5-substituiertem Pyrimidinring, ihre Herstellung und Verwendung |
DE19809635A1 (de) | 1998-03-06 | 1999-09-09 | Basf Ag | Verfahren zur Darstellung von Endothelinrezeptorantagonisten vom Sulfanyltyp |
DE19850301A1 (de) | 1998-10-30 | 2000-05-04 | Basf Ag | Verfahren zur Racematspaltung von 2-Hydroxypropionsäuren |
US7566452B1 (en) | 1999-05-04 | 2009-07-28 | New York University | Cancer treatment with endothelin receptor antagonists |
DE10002393A1 (de) * | 2000-01-20 | 2001-07-26 | Basf Ag | Verfahren zur enantioselektiven Herstellung von 3,3-Diphenyl-2,3-epoxypropionsäureestern |
US8168616B1 (en) | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
DE10064797A1 (de) * | 2000-12-22 | 2002-06-27 | Knoll Ag | Orale und parenterale pharmazeutische Formulierung, umfassend eine niedermolekulare Thrombininhibitor-Pro-Pharmakon |
WO2002064573A1 (fr) * | 2001-02-14 | 2002-08-22 | Abbott Gmbh & Co. Kg | Nouveaux derives d'acide carboxylique contenant des triazines a substitution alkyle, leur production et leur utilisation en tant qu'antagonistes du recepteur d'endotheline |
PT1243262E (pt) | 2001-03-20 | 2006-10-31 | Sanol Arznei Schwarz Gmbh | Nova utilizacao de uma classe de compostos peptideos para o tratamento da dor inflamatoria nao neuropatica |
PT1243263E (pt) | 2001-03-21 | 2003-03-31 | Sanol Arznei Schwarz Gmbh | Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma |
US6772708B2 (en) * | 2001-10-30 | 2004-08-10 | The Procter And Gamble Company | Wetness indicator having improved colorant retention |
DE10259382A1 (de) * | 2002-12-18 | 2004-07-01 | Abbott Gmbh & Co. Kg | 3-Substituierte 3,4-Dihydro-thieno[2,3-d]pyrimidin-4-on-Derivate, ihre Herstellung und Verwendung |
US20040204422A1 (en) | 2003-04-14 | 2004-10-14 | Abbott Gmbh & Co. Kg. | N-[(Piperazinyl)hetaryl]arylsulfonamide compounds |
GB0327839D0 (en) | 2003-12-01 | 2003-12-31 | Novartis Ag | Organic compounds |
TW200605867A (en) | 2004-03-17 | 2006-02-16 | Novartis Ag | Use of organic compounds |
EP1734980A1 (fr) | 2004-04-16 | 2006-12-27 | Schwarz Pharma Ag | Utilisation de composes peptidiques destinee a la prophylaxie et au traitement de maux de tete chroniques |
EP1604656A1 (fr) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Utilisation nouvelle de peptides pour le traitement de la sclérose amytrophique latérale (ALS) |
CA2573125A1 (fr) | 2004-08-27 | 2006-03-02 | Schwarz Pharma Ag | Nouvelle utilisation de composes peptidiques pour traiter la douleur liee au cancer des os, la douleur induite par la chimiotherapie et la therapie nucleosidique |
DE102005025161A1 (de) * | 2005-06-01 | 2006-12-07 | Phenion Gmbh & Co. Kg | Derivate des Pyrimidins und Triazins und deren Verwendung |
KR20080095885A (ko) * | 2006-01-20 | 2008-10-29 | 쉐링 코포레이션 | 벤젠설포닐-크로만, 티오크로만, 테트라하이드로나프탈렌 및 관련된 감마 세크라타제 억제제 |
BRPI0709950A2 (pt) * | 2006-04-13 | 2011-08-02 | Actelion Pharmaceuticals Ltd | uso de bosentan na preparação de um medicamento para o tratamento de fibrose pulmonar idiopática em estágio precoce e uso de antagonista do receptor endotelin |
EA027836B1 (ru) | 2006-06-15 | 2017-09-29 | ЮСиБи ФАРМА ГМБХ | Фармацевтическая комбинация для профилактики, облегчения и/или лечения приступов эпилепсии и ее применение |
US20080139593A1 (en) | 2006-12-12 | 2008-06-12 | Gerber Michael J | Method for treating a pulmonary hypertension condition |
EP2118073A2 (fr) * | 2007-02-02 | 2009-11-18 | Concert Pharmaceuticals Inc. | Antagonistes sélectifs des récepteurs de type a de l'endothéline |
CN101801936B (zh) * | 2007-07-31 | 2012-10-03 | 吉利德科罗拉多公司 | 安立生坦的代谢物和衍生物 |
US20090069353A1 (en) * | 2007-09-12 | 2009-03-12 | Protia, Llc | Deuterium-enriched ambrisentan |
DE102008037324A1 (de) | 2008-08-11 | 2010-02-18 | Ratiopharm Gmbh | Pharmazeutische Formulierung zur pulmonalen Blutdrucksenkung |
WO2010070658A2 (fr) * | 2008-11-05 | 2010-06-24 | Msn Laboratories Limited | Procédé amélioré de synthèse d'antagonistes de récepteur de l'endothéline |
DE202009009917U1 (de) | 2009-07-21 | 2010-02-11 | Ratiopharm Gmbh | Ambrisentan in spezifischer kristalliner Form |
WO2010091877A2 (fr) | 2009-02-13 | 2010-08-19 | Ratiopharm Gmbh | Procédé de production d'ambrisentan |
WO2011004402A2 (fr) | 2009-07-10 | 2011-01-13 | Cadila Healthcare Limited | Procédé amélioré de préparation d'ambrisentan et nouveaux intermédiaires associés |
WO2011022694A2 (fr) * | 2009-08-20 | 2011-02-24 | University Of Tennessee Research Foundation, The | Composés cannabinoïdes furanopyrimidine et méthodes dutilisation associées |
AU2010328230B2 (en) | 2009-12-07 | 2016-06-02 | Cardioxyl Pharmaceuticals, Inc. | Bis-acylated hydroxylamine derivatives |
ES2719101T3 (es) * | 2009-12-07 | 2019-07-08 | Univ Johns Hopkins | Derivados de hidroxilamina N-acilados y derivados de hidroxilamina o-acilados |
US20130060031A1 (en) * | 2010-03-15 | 2013-03-07 | Natco Pharma Limited | Process for the preparation of highly pure ambrisentan |
WO2012017441A1 (fr) | 2010-08-04 | 2012-02-09 | Natco Pharma Limited | Procédé amélioré pour la préparation d'acide s-2-hydroxy-3-méthoxy-3,3-diphénylpropionique |
KR20150002876A (ko) | 2010-10-15 | 2015-01-07 | 길리애드 사이언시즈, 인코포레이티드 | 폐 고혈압 치료의 조성물 및 방법 |
EP2476670A1 (fr) | 2011-01-07 | 2012-07-18 | Zentiva, K.S. | Seuls solides stabiles de l'ambrisentane |
CN102276536B (zh) * | 2011-06-10 | 2015-04-29 | 中国科学院化学研究所 | 一种光学纯的(+)-安倍生坦和光学纯的(+)-达芦生坦的制备方法 |
CN103012280B (zh) * | 2011-09-22 | 2015-04-29 | 江苏康缘药业股份有限公司 | 一种制备安立生坦的方法 |
KR101855506B1 (ko) | 2011-10-13 | 2018-05-08 | 주식회사 동진쎄미켐 | 방향족 고리 함유 고분자 및 이를 포함하는 레지스트 하층막 조성물 |
CA2852810A1 (fr) | 2011-10-19 | 2013-04-25 | Cipla Limited | Procede de preparation d'un antagoniste du recepteur de l'endotheline |
PL2867214T3 (pl) | 2012-06-29 | 2017-02-28 | Kern Pharma, S.L. | Sposób wytwarzania pochodnych kwasów karboksylowych i ich związków pośrednich |
CN103524424A (zh) * | 2012-07-04 | 2014-01-22 | 天津药物研究院 | 一种安立生坦的晶型vi及其制备方法和应用 |
CN103524425A (zh) * | 2012-07-04 | 2014-01-22 | 天津药物研究院 | 一种安立生坦的晶型v及其制备方法和应用 |
CN104098462B (zh) * | 2013-04-12 | 2017-11-17 | 江苏豪森药业集团有限公司 | 2‑羟基‑3‑甲氧基‑3,3‑二苯基丙酸消旋物的拆分方法 |
CN104592129B (zh) * | 2013-10-30 | 2019-04-16 | 武汉启瑞药业有限公司 | 一种改进的制备安立生坦的方法 |
CN103709106A (zh) * | 2013-12-06 | 2014-04-09 | 石家庄博策生物科技有限公司 | 一种立体选择性制备安立生坦的方法 |
CN104744231A (zh) * | 2013-12-26 | 2015-07-01 | 天津药物研究院 | 一种拆分2-羟基丙酸消旋体的方法 |
CN105801404B (zh) * | 2014-12-31 | 2019-01-08 | 辽宁远大诺康生物制药有限公司 | 一种s-2-羟基-3-甲氧基-3,3-二苯基丙酸及其制备方法 |
CN106699626B (zh) * | 2015-11-13 | 2019-08-16 | 辽宁远大诺康生物制药有限公司 | 一种2-羟基-3-甲氧基-3,3-二苯基丙酸盐消旋体的制备方法 |
EP3235496A1 (fr) | 2016-04-19 | 2017-10-25 | Noorik Biopharmaceuticals AG | Traitement de l'insuffisance rénale aiguë |
CN109705042B (zh) * | 2017-10-26 | 2021-12-21 | 正大天晴药业集团股份有限公司 | 一种安立生坦的制备方法 |
WO2024092240A1 (fr) | 2022-10-28 | 2024-05-02 | Chinook Therapeutics, Inc. | Traitement de la néphropathie à iga à l'aide d'un antagoniste du récepteur de l'endothéline et d'un anticorps de liaison à april |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE403578C (de) | 1924-10-02 | Walter Beige | Verfahren zum Innen-Emaillieren von Roehren | |
JPS5729445B2 (fr) | 1974-06-25 | 1982-06-23 | ||
GB8912700D0 (en) | 1989-06-02 | 1989-07-19 | Shell Int Research | Herbicidal compounds |
JP2771604B2 (ja) * | 1988-06-20 | 1998-07-02 | クミアイ化学工業株式会社 | 除草剤及びその有効成分となる新規なアルカン酸誘導体 |
DE68914197T2 (de) * | 1988-06-20 | 1994-11-10 | Ihara Chemical Ind Co | Alkansäurederivate und herbizide Mittel. |
JPH0331266A (ja) | 1989-06-27 | 1991-02-12 | Nissan Chem Ind Ltd | ピリミジン誘導体及び除草剤 |
US5270289A (en) | 1989-07-19 | 1993-12-14 | Schering Aktiengesellschaft | Herbicidal dimethoxy pyrimidinyloxy-fluorinated acids and salts |
IL94999A (en) | 1989-07-19 | 1994-10-07 | Schering Ag | History of Acid (A-pyrimidinyloxy) Theo (and A-triazinyloxy) Theo (carboxylic, and herbicides containing them) |
FR2650365B1 (fr) | 1989-07-28 | 1991-11-22 | Caillau Ets | Raccord rapide |
JPH03240777A (ja) | 1990-02-20 | 1991-10-28 | Ube Ind Ltd | 脂肪酸誘導体、その製造法及び除草剤 |
DE4029648A1 (de) | 1990-09-19 | 1992-03-26 | Hoechst Ag | 4-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide |
CA2053603A1 (fr) * | 1990-10-19 | 1992-04-20 | Katsumasa Harada | Derive d'acide 3-alkoxyalcanoique, procede d'obtention et herbicide qui en contient. |
JPH05125058A (ja) * | 1990-10-19 | 1993-05-21 | Ube Ind Ltd | 3−アルコキシアルカン酸化合物、その中間体、その製造法及び除草剤 |
DE4035758A1 (de) | 1990-11-08 | 1992-05-14 | Schering Ag | Substituierte (alpha)-pyrimidinyloxy(thio)- und (alpha)-triazinyloxy(thio)-carbonsaeurederivate, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider, fungizider und pflanzenwachstumsregulierender wirkung |
JP2730021B2 (ja) | 1991-05-31 | 1998-03-25 | 宇部興産株式会社 | 3−ベンジルオキシアルカン酸誘導体、その製造法及び除草剤 |
JP2730022B2 (ja) * | 1991-06-07 | 1998-03-25 | 宇部興産株式会社 | 3−アルコキシブチリルイミダゾール誘導体、その製造法及び除草剤 |
EP0517215B1 (fr) * | 1991-06-07 | 1998-09-02 | Ube Industries, Ltd. | Dérivés de pyrimidine ou triazine, procédé pour leur préparation et herbicides les contenant |
DE4123469A1 (de) | 1991-07-16 | 1993-01-21 | Basf Ag | Herbizide mittel, die n-dichloracetyl-diazacycloalkane als antagonistische verbindungen enthalten |
AU2945392A (en) * | 1991-12-10 | 1993-07-19 | Hoechst Schering Agrevo Gmbh | Pyrimidinyl- or triazinyl-oxy(or thio)aldehyde derivatives and their use as herbicides or plant-growth regulators |
DE4142570A1 (de) | 1991-12-21 | 1993-06-24 | Basf Ag | Glykolaldehyd- und milchsaeurederivate, deren herstellung und verwendung |
DE4201875A1 (de) | 1992-01-24 | 1993-07-29 | Basf Ag | Thiocarbonsaeurederivate, verfahren und zwischenprodukte zu ihrer herstellung |
US5376620A (en) | 1992-04-17 | 1994-12-27 | Ube Industries, Ltd. | Sulfonamide derivative, process for preparing the same and herbicide using the same |
EP0601155A1 (fr) * | 1992-06-17 | 1994-06-15 | Novartis AG | Composes de pyrimidinyle et de triazinyle a activite herbicide |
US5541148A (en) | 1992-07-08 | 1996-07-30 | Ciba-Geigy Corporation | Selective safened herbicidal composition comprising 2-ethoxycarbonyl-3-(4,6-dimethoxypyrimidine-2-yl) oxy-pyridine and an acylsulfamoylphenyl-urea safener |
EP0671880A1 (fr) | 1992-07-08 | 1995-09-20 | Ciba-Geigy Ag | Composition herbicide selective |
JP2985992B2 (ja) | 1992-07-21 | 1999-12-06 | 宇部興産株式会社 | 3−アルコキシ−n−シクロアルキルスルホニルアルカン酸アミド誘導体、その製造法及び除草剤 |
DE4313412A1 (de) | 1993-04-23 | 1994-10-27 | Basf Ag | 3-(Het)aryl-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung |
DE4313413A1 (de) | 1993-04-23 | 1994-10-27 | Basf Ag | 3-(Het)aryloxy(thio)-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung |
DE69423258T2 (de) * | 1993-06-03 | 2000-07-13 | Kanegafuchi Chemical Ind | Härtbare Zusammensetzung |
DE4335950A1 (de) * | 1993-10-21 | 1995-04-27 | Basf Ag | Derivate von 3-Hydroxycarbonsäuren, deren Herstellung und Verwendung |
DE4411225A1 (de) | 1994-03-31 | 1995-10-05 | Basf Ag | Verwendung von Carbonsäurederivaten als Arzneimittel |
AU2882195A (en) | 1994-06-27 | 1996-01-19 | Ciba-Geigy Ag | Pyrimidinyl- and triazinyl-oxy and thio-3-haloalkyl-propionic acid derivatives as herbicides |
DE19533023B4 (de) | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
AU703618B2 (en) | 1994-10-21 | 1999-03-25 | Glaxo Wellcome Inc. | Medicament carrier for dry powder inhalator and process for forming the same |
US6030975A (en) | 1997-03-14 | 2000-02-29 | Basf Aktiengesellschaft | Carboxylic acid derivatives, their preparation and use in treating cancer |
AU750755B2 (en) | 1997-09-26 | 2002-07-25 | Abbvie Deutschland Gmbh & Co Kg | Endothelin antagonist and a renin-angiotensin system inhibitor as a combined preparation |
DE19743143A1 (de) | 1997-09-30 | 1999-04-01 | Knoll Ag | Pharmazeutische Kombinationspräparate |
DE19754082A1 (de) | 1997-12-05 | 1999-06-10 | Knoll Ag | Methode zur Bekämpfung der Fettleibigkeit |
DE19850301A1 (de) | 1998-10-30 | 2000-05-04 | Basf Ag | Verfahren zur Racematspaltung von 2-Hydroxypropionsäuren |
DE10002393A1 (de) | 2000-01-20 | 2001-07-26 | Basf Ag | Verfahren zur enantioselektiven Herstellung von 3,3-Diphenyl-2,3-epoxypropionsäureestern |
EP1946502B2 (fr) | 2006-07-12 | 2017-09-13 | Huawei Technologies Co., Ltd. | Procédé de cotnrôle d'encombrement |
CN101801936B (zh) | 2007-07-31 | 2012-10-03 | 吉利德科罗拉多公司 | 安立生坦的代谢物和衍生物 |
-
1995
- 1995-09-07 DE DE19533023A patent/DE19533023B4/de not_active Expired - Fee Related
- 1995-10-07 AT AT95935916T patent/ATE204568T1/de active
- 1995-10-07 ES ES01103889T patent/ES2226996T3/es not_active Expired - Lifetime
- 1995-10-07 US US12/481,594 patent/USRE42462E1/en not_active Expired - Lifetime
- 1995-10-07 AT AT01103889T patent/ATE277911T1/de not_active IP Right Cessation
- 1995-10-07 DE DE122008000049C patent/DE122008000049I1/de active Pending
- 1995-10-07 CA CA002201785A patent/CA2201785C/fr not_active Expired - Lifetime
- 1995-10-07 CZ CZ19971132A patent/CZ294603B6/cs not_active IP Right Cessation
- 1995-10-07 US US08/809,699 patent/US5932730A/en not_active Ceased
- 1995-10-07 DK DK95935916T patent/DK0785926T3/da active
- 1995-10-07 KR KR1019970702413A patent/KR100438339B1/ko not_active IP Right Cessation
- 1995-10-07 HU HU9701975A patent/HU220621B1/hu active Protection Beyond IP Right Term
- 1995-10-07 CN CN2006100999548A patent/CN1923820B/zh not_active Expired - Lifetime
- 1995-10-07 BR BR9509338A patent/BR9509338A/pt not_active Application Discontinuation
- 1995-10-07 EP EP95935916A patent/EP0785926B1/fr not_active Expired - Lifetime
- 1995-10-07 JP JP51291196A patent/JP3957748B2/ja not_active Expired - Lifetime
- 1995-10-07 UA UA97052223A patent/UA45985C2/uk unknown
- 1995-10-07 EP EP01103889A patent/EP1110952B9/fr not_active Expired - Lifetime
- 1995-10-07 RU RU97107617/04A patent/RU2180335C2/ru active Protection Beyond IP Right Term
- 1995-10-07 DE DE59510949T patent/DE59510949D1/de not_active Expired - Lifetime
- 1995-10-07 SI SI9520110A patent/SI9520110A/sl unknown
- 1995-10-07 CN CNB2004100027833A patent/CN1293059C/zh not_active Expired - Lifetime
- 1995-10-07 MX MX9702658A patent/MX9702658A/es unknown
- 1995-10-07 ES ES95935916T patent/ES2162942T3/es not_active Expired - Lifetime
- 1995-10-07 CN CNB951956558A patent/CN1142918C/zh not_active Expired - Lifetime
- 1995-10-07 PT PT95935916T patent/PT785926E/pt unknown
- 1995-10-07 WO PCT/EP1995/003963 patent/WO1996011914A1/fr active IP Right Grant
- 1995-10-07 DE DE59509541T patent/DE59509541D1/de not_active Expired - Lifetime
- 1995-10-11 IL IL11556095A patent/IL115560A/xx not_active IP Right Cessation
- 1995-10-13 ZA ZA958642A patent/ZA958642B/xx unknown
- 1995-10-13 HR HR950517A patent/HRP950517B1/xx not_active IP Right Cessation
- 1995-10-17 TW TW084110900A patent/TW577880B/zh not_active IP Right Cessation
-
1997
- 1997-03-27 NZ NZ294849A patent/NZ294849A/en not_active IP Right Cessation
- 1997-03-27 US US12/481,598 patent/USRE42477E1/en not_active Expired - Lifetime
- 1997-03-27 PL PL95319655A patent/PL186850B1/pl unknown
- 1997-04-11 FI FI971529A patent/FI120492B/fi not_active IP Right Cessation
- 1997-04-11 NO NO971675A patent/NO308846B1/no not_active IP Right Cessation
-
1998
- 1998-11-02 US US09/184,152 patent/US5969134A/en not_active Expired - Lifetime
-
1999
- 1999-05-11 US US09/309,770 patent/US6197958B1/en not_active Expired - Lifetime
-
2000
- 2000-12-27 US US09/748,184 patent/US6600043B2/en not_active Expired - Lifetime
-
2001
- 2001-10-18 GR GR20010401798T patent/GR3036931T3/el unknown
-
2003
- 2003-06-24 US US10/602,275 patent/US7109205B2/en not_active Expired - Fee Related
-
2004
- 2004-04-22 HR HR20040364A patent/HRP20040364B1/xx not_active IP Right Cessation
- 2004-12-01 HK HK04109463A patent/HK1066541A1/xx not_active IP Right Cessation
-
2006
- 2006-03-16 US US11/377,879 patent/US7119097B2/en not_active Expired - Fee Related
- 2006-08-10 US US11/502,293 patent/US7601730B2/en not_active Expired - Fee Related
- 2006-08-10 US US11/502,257 patent/US20060276645A1/en not_active Abandoned
-
2007
- 2007-02-21 JP JP2007040759A patent/JP4512106B2/ja not_active Expired - Lifetime
- 2007-02-21 JP JP2007040758A patent/JP4512105B2/ja not_active Expired - Lifetime
- 2007-02-21 JP JP2007040761A patent/JP5160797B2/ja not_active Expired - Lifetime
- 2007-02-21 JP JP2007040760A patent/JP4787184B2/ja not_active Expired - Lifetime
- 2007-04-25 US US11/789,630 patent/US7582647B2/en not_active Expired - Fee Related
- 2007-09-04 HK HK07109567.7A patent/HK1104293A1/xx not_active IP Right Cessation
-
2008
- 2008-10-15 LU LU91487C patent/LU91487I2/fr unknown
- 2008-10-15 NL NL300361C patent/NL300361I2/nl unknown
- 2008-10-17 NO NO2008015C patent/NO2008015I2/no unknown
- 2008-10-21 FR FR08C0041C patent/FR08C0041I2/fr active Active
-
2009
- 2009-08-17 US US12/542,050 patent/US7863445B2/en not_active Expired - Fee Related
-
2010
- 2010-12-03 US US12/959,849 patent/US20110178294A1/en not_active Abandoned
-
2011
- 2011-10-06 US US13/267,178 patent/US8349843B2/en not_active Expired - Fee Related
-
2012
- 2012-02-01 JP JP2012019532A patent/JP5700378B2/ja not_active Expired - Lifetime
- 2012-11-27 US US13/686,182 patent/US20130317044A1/en not_active Abandoned